Clinical outcomes in pediatric hemodialysis patients in the USA: lessons from CMS’ ESRD CPM Project by Neu, Alicia M. & Frankenfield, Diane L.
EDUCATIONAL REVIEW
Clinical outcomes in pediatric hemodialysis patients
in the USA: lessons from CMS’ ESRD CPM Project
Alicia M. Neu & Diane L. Frankenfield
Received: 7 January 2008 /Revised: 21 February 2008 /Accepted: 18 March 2008 / Published online: 29 May 2008
# IPNA 2008
Abstract Although prospective randomized trials have
provided important information and allowed the develop-
ment of evidence-based guidelines in adult hemodialysis
(HD) patients, with approximately 800 prevalent pediatric
HD patients in the United States, such studies are difficult
to perform in this population. Observational data obtained
through the Center for Medicare & Medicaid Services’
(CMS’) End Stage Renal Disease (ESRD) Clinical Perfor-
mance Measures (CPM) Project have allowed description
of the clinical care provided to pediatric HD patients as well
as identification of risk factors for failure to reach adult
targets for clinical parameters such as hemoglobin, single-
pool Kt/V (spKt/V) and serum albumin. In addition, studies
linking data from the ESRD CPM Project and the United
States Renal Data System have allowed evaluation of
associations between achievement of those targets and the
outcomes of hospitalization and death. The results of those
studies, while unable to prove cause and effect, suggest that
the adult ESRD CPM targets may assist in identifying
pediatric HD patients at risk for poor outcomes.
Keywords Pediatric.Hemodialysis.Outcomes.Clinical
performancemeasures.CPM.Hospitalization.Mortality
Introduction
The gold standard in clinical research is the prospective
randomized controlled study and trials such as the National
Cooperative Dialysis Study performed in the 1970s and
more recently the Hemodialysis (HEMO) Study have
provided important information that has supported the
development of evidence-based guidelines for the clinical
care of adult hemodialysis (HD) patients [1–3]. Such
studies are difficult to perform in pediatric HD patients
given the limited number of patients and the fact that,
because kidney transplantation is the treatment of choice for
the majority of pediatric end-stage kidney disease (ESRD)
patients, dialysis is often provided as a relatively short-term
therapy until transplantation can be performed. Figure 1
shows the prevalent pediatric ESRD population in the
United States from 2005 and demonstrates that whereas
>40% of patients at ESRD initiation are on HD, the
majority of patients who have had ESRD for 24 months
or longer have received a kidney transplant [4]. Thus, the
pediatric ESRD population is small and fluid, moving from
dialysis to kidney transplant to chronic kidney disease and
back to dialysis or transplant, making prospective study in
patients on any single modality difficult. This limitation is
coupled with the fact that the incidences of hard outcomes
such as mortality are relatively low when compared with
adult ESRD patients [4].
Although large-scale, prospective randomized studies in
pediatric HD patients are lacking, there are several
observational studies that have provided important infor-
mation regarding the care provided to pediatric ESRD
patients. An example is the Centers for Medicare &
Medicaid Services’ (CMS’) ESRD Clinical Performance
Measures (CPM) Project. Since 2000, the ESRD CPM
Project has collected clinical data on pediatric HD patients
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[5–12]. In addition, several studies have linked the
intermediate outcomes collected by the ESRD CPM Project
with administrative data from the USRDS in an effort to
demonstrate associations between the attainment of certain
clinical targets (such as a hemoglobin ≥ 11 g/dl) and
morbidity and mortality [13–15]. Although these studies
have added significantly to the information available to
those who care for children on HD, it is important to
understand the limitations of these data—perhaps most
importantly the inability of these studies to demonstrate
causality. The purpose of this article is to review data
available on pediatric HD patients from the ESRD CPM
Project and studies linking data from the ESRD CPM
Project with USRDS administrative data. To elucidate the
strengths and limitations of these data, the history and
structure of the ESRD CPM Project will be reviewed
briefly. A detailed history of the project can be found on the
CMS Web site (www.cms.hhs.gov/CPMProject).
History and background of CMS’ ESRD CPM project
All patients with ESRD in the United States, including
children, have been eligible to receive Medicare coverage
since 1972. As part of its oversight of the Medicare
program, CMS contracts with 18 ESRD network organ-
izations throughout the United States to monitor the quality
of care for ESRD patients and to facilitate improvements in
that care. Since 1994, this quality assurance effort has
included collection of clinical parameters in the areas of
anemia management, dialysis adequacy, and serum albumin
[5, 16]. In 1997, CMS funded the development of Clinical
Performance Measures (CPMs) to be based on the National
Kidney Foundation (NKF) Dialysis Outcomes Quality
Initiative (DOQI) Guidelines [17–20]. Sixteen ESRD
CPMs were developed that have subsequently been reduced
to 13: three for HD adequacy, three for peritoneal dialysis
(PD) adequacy, three for vascular access, and four for
anemia management [5]. A full description of the CPMs is
p r e s e n t e do nt h eC M SW e bs i t e( www.cms.hhs.gov/
CPMProject)[ 5]. Similar to the KDOQI guidelines on
which they are based, the ESRD CPMs establish targets for
the frequency of monitoring the various clinical parameters,
as well as thresholds or targets for the parameters
themselves. That is, within the anemia-management CPMs,
the target level for hemoglobin is specified, as is the
frequency of monitoring serum transferrin saturation (TSAT)
and serum ferritin and the target values for serum TSATand
serum ferritin [5]. In addition to collecting information
necessary to calculate the ESRD CPMs, the project also
collects information on other aspects of dialysis care. In
particular, although measurement of or obtaining a certain
level of serum albumin is not a CPM, these data are felt to
be an important indicator of care, so they are collected and
reported by the ESRD CPM Project [5]. It should be noted
that the ESRD CPMs are for adult dialysis patients, and at
present, there are no pediatric ESRD CPMs [5].
In 1999 the ongoing quality assurance data collection
effort by the networks was merged with the ESRD CPM
Project, and since that time, the project has collected data
on a random sampling of adult HD and PD patients [5]. The
results of these data collection efforts are reported in an
annual report (www.cms.hhs.gov/CPMProject) as well as in
more than 50 publications [5]. Data on pediatric dialysis
patients were not collected until the 2000 study year.
Figure 2 diagrams the timeline of data collection expansion
to include pediatric dialysis patients. It should be noted that
unlike the random sampling that occurs in adult dialysis
patients, data are collected on all pediatric patients on
dialysis at the time of the data collection. Furthermore,
identifying pediatric dialysis patients for data collection is
not restricted to patients who have Medicare as primary
payer for their dialysis services. Thus, all pediatric dialysis
patients, regardless of insurance coverage, will be identified
and have data submitted to the ESRD CPM Project.
Because this article focuses on outcomes studies in
pediatric HD patients, the remainder of the description of
the data collection effort discusses the procedure for
patients on that modality.
Data collection for ESRD CPM Project
The data collection for the ESRD CPM Project occurs in
the spring of each study year, when a five-page data
collection form is distributed to all facilities that have been
identified by the 18 ESRD networks as having a pediatric
Fig. 1 Prevalent patient distribution by modality for pediatric (0–
19 years) end-stage renal disease patients for 2005, taken from the
2007 United States Renal Data Systems Annual Report (USRDS) [4]
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December 31 of the preceding year. The dialysis facilities
provide clinical information abstracted from patients’
medical records for the months of October, November,
and December of the preceding year. That is, for the 2006
CPM study year, data are abstracted from October through
December 2005 on any pediatric patient alive and on in-
center HD as of 31 December 2005. Demographic
information provided by the facility includes gender, race,
ethnicity, age, primary cause of ESRD, and date of first
dialysis. Information used to assess the dialysis care
provided to these patients includes patient height, pre- and
postdialysis weight, pre- and postdialysis blood urea
nitrogen (BUN) values, dialysis session length, dialyzer
KUf values, reported urea reduction ratios and reported Kt/
V values, type of vascular access [catheter, arteriovenous
fistula (AVF), arteriovenous graft (AVG)], blood-pump
flow rates, monitoring of the access site for stenosis,
monthly hemoglobin, TSAT, serum ferritin, and serum
albumin values [with the associated laboratory method—
bromcresol green (BCG) or bromcresol purple (BCP) [21],
as these two methods have been shown to yield systemat-
ically different results], erythropoietin dose and route of
administration, and iron prescription information. Although
reported Kt/V values are collected on the data collection
form, single-pool Kt/V (spKt/V) values presented in the
annual report and used for subsequent analysis are
calculated from the raw data points using the Daugirdis II
formula [22]. Height, weight, and body mass index (BMI)
standard deviation scores (SDS) are calculated using the
appropriate gender-/age-specific mean, SD and adjustment
parameters for the national population derived from the
Third National Health and Nutrition Examination Survey
(NHANES III) (2000) of the National Center for Health
Statistics [23]. Although data are requested on all prevalent
pediatric HD patients, to remain in the analysis, a patient
must have the minimum data elements submitted, which
include a completed data collection form with at least one
monthly hemoglobin value, at least one paired pre- and
postdialysis BUN value, and at least one serum albumin
value over the 3-month study period [5].
General limitations and strengths of the ESRD CPM
Project
Now that the process of the ESRD CPM Project has been
described, before presenting the data from that project, it is
important to reiterate some of the key points of the data
collection process that highlight the strengths and weak-
nesses of the data and their applicability to pediatric HD
patients in general. First and foremost, data collection
occurs on a prevalent, not incident, population. That is,
patients are not enrolled at the time of dialysis initiation and
followed over time; rather, the ESRD CPM Project
provides a snapshot of the care provided over a 3-month
period to patients on dialysis at the time of data collection.
It cannot be assumed that these 3 months accurately reflect
the long-term status of the patient. The second general
limitation of the data collection is that many factors that
may impact the ability to attain the various threshold
values, such as adherence to prescribed oral therapies,
adherence to dialysis treatments, markers of inflammation
beyond serum albumin and serum ferritin, and nutritional
assessment beyond height, weight and serum albumin, are
not collected by the ESRD CPM Project and therefore any
influence cannot be evaluated or factored. Finally, the
ESRD CPM Project focuses on intermediate outcomes of
anemia management, vascular access, dialysis adequacy,
and serum albumin and does not collect data on the more
firm clinical outcomes of neurocognitive development,
hospitalization, or mortality. Although data on linear
growth, another clinical outcome in pediatric patients, are
collected, data on factors that may affect linear growth,
such as Tanner stage, calcium and phosphorous balance,
and prescription of recombinant human growth hormone,
have not been routinely collected [5]. Finally, measures of
quality of life are not obtained, although a special analysis
to evaluate quality of life in pediatric dialysis patients in
several ESRD networks is underway [24].
Although data on hospitalization and mortality are not
available in the ESRD CPM Project, they are available in
the United States Renal Data System (USRDS) [4]. Thus,
CMS’ CPM ESRD Project
2000 Study Year
Data collection begins on ALL adolescent
(age 12 to < 18 yrs) HD patients
2002 Study Year
Data collection expanded to ALL pediatric
(age 0 to < 18 yrs) HD patients
2005 Study Year
Data collection expanded to ALL pediatric
(age 0 to < 18 yrs) HD and PD patients
1999 
Data collection begins on random sampling
of adult (≥ 18 yrs) HD and PD patients
Fig. 2 Timeline for expansion of End-Stage Renal Disease Clinical
Performance Measures (ESRD CPM) Project to include data collec-
tion on pediatric dialysis patients [5]
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Project with hospitalization and mortality data in USRDS,
associations between achieving threshold values for the
adult ESRD CPMs and hospitalization and mortality can be
evaluated. A full description of the USRDS, including
details of how to obtain data from the USRDS and ESRD
CPM Project for research, is available in a published annual
report and on the Internet (www.usrds.org)[ 4]. It should be
noted that although all ESRD patients in the United should
have a file in USRDS, information in the USRDS on
hospitalization are obtained from Medicare billing claims.
Therefore, only patients for whom a bill was submitted to
Medicare will have that hospitalization data captured [4].
The strengths of the ESRD CPM Project data set lie in
the fact that it captures information on all prevalent
pediatric HD patients, unlike data collection in adult
dialysis patients, which occurs on a representative sample.
Not only does the ESRD CPM Project allow evaluation of
the universe of pediatric HD patients in each study year,
but patients who remain on dialysis will have data
submitted in sequential study years, allowing longitudinal
assessment of clinical parameters in a subgroup of
patients. Finally, data for the ESRD CPM Project are
collected for monitoring clinical care, and outlying values
are verified [5]. This is in contrast to data obtained from the
USRDS, for example, where data are abstracted from forms
completed for administrative purposes and are not validated
or verified [4].
Intermediate outcomes in pediatric HD patients
As stated previously, the ESRD CPM Project produces an
annual report that provides data collected on the prevalent
dialysis population for that study year. For the 2006 study
year, 803 pediatric patients were identified as being alive
and on HD as of 31 December 2005 [5]. Of these, 743
(93%) had the minimum data submitted to be included in
the sample [5]. Table 1 shows the clinical parameters, or
intermediate outcomes, of this prevalent population of
patients. The annual report also demonstrates that the
majority of prevalent pediatric HD patients receive their
dialysis by way of a catheter (61%) as opposed to an AVF
( 3 1 % )o rA V G( 8 % )[ 5]. Although formal statistical
analyses are not performed, the annual report shows the
percentage of patients achieving the various threshold
values and demonstrates, for example, that in the area of
urea clearance, a lower percentage of black than white
patients (86% vs 90%), a lower percentage of patients on
dialysis for less than 6 months versus 6 months or longer
(72% vs 92%), and a lower percentage of patients with
serum albumin < 3.5/3.2 g/dl (BCG/BCP) than those with
mean serum albumin levels higher than these thresholds
(82% vs 89%) had a mean spKt/V ≥ 1.2 [5]. Again,
statistical analyses are not performed for the annual report.
Therefore, data in the annual report describes the prevalent
dialysis population and identifies the percentage of patients
who achieve the adult ESRD CPMs, but it does not
evaluate whether the differences in the percentage of
patients achieving targets is statistically significant, nor
does it control for factors that might impact the ability to
meet thresholds or targets.
Several studies have used the data from the ESRD CPM
Project and performed multivariate analysis specifically to
delineate risk factors for failing to meet these threshold
values [6, 7]. A study by Frankenfield et al. used data from
the 2000 study year, which included 433 adolescent (age 12
to < 18 years) HD patients [6]. The results of multivariate
logistic regression analysis to identify factors predictive of
failing to reach threshold values for spKt/V, serum albumin,
and hemoglobin are shown in Table 2 [6]. Perhaps most
notably, black patients were significantly less likely to
achieve an spKt/V ≥ 1.2 than were white patients, despite
controlling for multiple possible confounding variables [6].
Also of note, failure to meet the threshold for either serum
albumin or hemoglobin was a risk factor for failing to
meet the threshold for the other (Table 2)[ 6]. A
subsequent analysis evaluated data from the 2001 study
year, which included 435 patients aged 12 to < 18 years on
HD, and focused entirely on risk factors for anemia, defined
as hemoglobin < 11 g/dl [7]. In multivariate analysis,
factors that remained predictive of anemia in the final
model included duration of dialysis less than 6 months
[odds ratio (OR) 3.5, 95% confidence interval (CI) 1.9,
6.5], mean serum albumin < 3.5/3.2 g/dl (BCG/BCP) (OR
3.2, 95% CI 1.8, 5.8) and mean TSAT < 20% (OR 1.9, 95%
CI 1.2, 3.2) [7].
Together, these two studies identify factors that are
associated with failure to reach target values for urea
clearance, hemoglobin, and serum albumin. However, it
Table 1 Clinical parameters in 743 pediatric (< 18 years) hemodial-
ysis patients from the 2006 End-Stage Renal Disease Clinical
Performance Measures (ESRD CPM) Project
Clinical
Parameter
Mean ± Standard
Deviation
Percent equal to or
greater than Threshold
spKt/V 1.58±0.33 88% ≥ 1.2
Hemoglobin 11.5±1.6 g/dl 68% ≥ 11 g/dl
Transferrin
Saturation
29±14% 74% ≥ 20%
Serum Ferritin 471±471 ng/ml 83% ≥ 100 ng/ml
Serum Albumin 3.9±0.5/3.5 ± 0.5 g/dl
(BCG/BCP)
80% ≥ 3.5/3.2 g/dl
(BCG/BCP)
Data are from October through December 2005 [5]
spKt/V single-pool Kt/V as calculated by the Daugirdas II formula,
BCG/BCP bromcresol green and bromcresol purple laboratory method
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period and may not, therefore, be reflective of the typical
status of the patient. In fact, an analysis of longitudinal data
revealed that among patients who had data submitted to two
consecutive study years, a significant percentage of patients
who failed to meet threshold values for spKt/V, serum
albumin, and hemoglobin in the first study year exceeded
those values in the following year [8]. It is also important to
reiterate that these data evaluate the likelihood that pediatric
HD patients will achieve a threshold value and do not
evaluate whether or not achievement of that threshold is, in
fact, associated with an improvement in patient outcome.
Association between achievement of adult ESRD CPMs
and clinical outcomes
Height and linear growth
Several studies have delineated associations between the
achievement of the adult targets collected by the ESRD
CPM Project and clinical outcomes, specifically height/
linear growth, hospitalization, and mortality [8–10, 12–14].
A study by Gorman et al. used data from the 2002 ESRD
CPM study year to determine clinical predictors of short
stature, defined as a height SDS < −1.88, which corre-
sponds to the third percentile for age and gender [10]. The
2002 study year contained information on 651 pediatric
(age < 18 years old) HD patients, of whom 266 (41%) had a
height SDS < −1.88 [10]. Multivariate analyses were done
separately in patients aged 10 to < 15 years of age and
those 15 to < 18 years of age, the results of which are
shown in Tables 3 and 4, respectively [10]. The number of
patients < 10 years of age was too small (90) to allow
statistical analysis in this subgroup [10].
In a more recent analysis, Gorman and colleagues
evaluated linear growth, that is, change in height SDS, in
407 patients who had data submitted to two or more
consecutive ESRD CPM study years [12]. In multivariate
analysis, younger age, longer duration on dialysis, and
increasing normalized protein catabolic rate (nPCR) were
associated with a worsening in height SDS over subsequent
ESRD CPM study years [–0.20 height SDS/year (95% CI –
0.3, –0.1) for < 13 years old vs ≥ 13 years old; –0.03 height
SDS/year (95% CI -0.14, -0.08) for duration of dialysis ≥
6 months vs < 6 months; –0.02 height SDS/year (95% CI –
0.04, –0.001) for each 0.1 increase in nPCR] [12].
Conversely, female patients and patients who had lower
height SDS in their first year of data entry into the ESRD
CPM Project had improvement in their height SDS over
time [+0.10 height SDS/year (95% CI 0.02, 0.19) for girls
vs boys; +0.03 height SDS/year (95% CI 0.01,0.05) for
each 0.5 decrease in height SDS] [12]. Etiology of ESRD,
race, ethnicity, and achieving target values for hemoglobin,
spKt/V, or serum albumin were not significantly associated
with either an improvement or worsening in height SDS
[12]. These studies suggest that younger age and longer
duration of dialysis are associated both with short stature
and poor linear growth, even after controlling for multiple
possible confounders [10, 12]. It should be reiterated,
Table 2 Factors remaining predictive of achieving threshold values for single-pool Kt/V (spKt/V), mean hemoglobin, and mean serum albumin
in 433 adolescent hemodialysis (HD) patients after multivariate logistic regression analyses
Clinical Parameter Threshold Factor Odds Ratio 95% Confidence Interval
spKt/V ≥ 1.2 Female gender 2.8 1.4, 5.9
Black race 0.43 0.21, 0.86
Body surface area (highest quartile = referent)
Quartile 1 91.6 23.3, 360.2
Quartile 2 35.4 11.6, 107.9
Quartile 3 9.3 3.6, 24.1
Mean serum albumin ≥ 3.5/3.2 g/dl (BCG/BCP) 3.2 1.4,7.3
Increasing mean dialysis session length (min) 1.03 1.02,1.05
Increasing mean blood-pump flow rate (ml/min) 1.016 1.010,1.021
Serum albumin ≥ 3.5/3.2 g/dl (BCG/BCP) Hispanic ethnicity 2.6 1.1, 5.8
Duration of dialysis (2 + years = referent)
< 0.5 years 0.24 0.12, 0.47
0.5–0.9 years 0.43 0.20, 0.93
1.0–1.9 years NS
Increasing mean hemoglobin (g/dl) 1.5 1.3, 1.8
Hemoglobin ≥ 11 g/dl Lower mean erythropoietin dose (U/kg/dose) 0.990 0.986, 0.994
Mean serum albumin ≥ 3.5/3.2 g/dl (BCG/BCP) 4.2 2.2, 7.9
Factors entered into the models included age, duration of dialysis, cause of end-stage renal disease, access type, body surface area, gender,
increasing hemoglobin, increasing spKt/V, and increasing serum albumin [6]
BCG/BCP bromcresol green/bromcresol purple laboratory method
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and which are necessary to interpret relationships between
intermediate outcomes and linear growth, such as protein
intake, use of recombinant growth hormone, Tanner stage,
and bone age, are not collected by the ESRD CPM Project.
Hospitalization and mortality
To evaluate possible associations of the intermediate
outcome data obtained by the ESRD CPM Project with
the outcomes of hospitalization and mortality, several
studies have linked data from the ESRD CPM Project and
the USRDS [13–15]. In one study, data from the 2000 and
2001 ESRD CPM study years were linked with hospitali-
zation data from USRDS through 29 January 2001 and
mortality data through 15 October 2001 to evaluate
associations between attainment of a spKt/V ≥ 1.2 and risk
for hospitalization and mortality [13]. Recall that these
ESRD CPM study years included only adolescent (age 12
to < 18 years) HD patients [13]. In this study, spKt/V
values were available from the ESRD CPM Project on 613
adolescent HD patients, with repeated measures (i.e. values
submitted to sequential study years) in 160 (26%) of those
patients [13]. Median follow-up for hospitalizations was
7.4±3.8 months and 10.8±2.9 months for mortality [13].
The number of deaths in the cohort was very small at 14,
with a mortality rate of 2.0 deaths/100 patient years [13].
The unadjusted hazard rate of death for patients with a
spKt/V < 1.2 compared with those with a spKt/V ≥ 1.2 was
2.90 (95% CI 0.75, 9.51) [13]. Given the small number of
deaths, multivariate analysis of mortality rates were not
performed [13]. Comparison of hospitalization rates
revealed that the unadjusted hospitalization rate ratio for
spKt/V < 1.2 versus ≥ 1.2 was 1.45 (95% CI 1.00, 2.05)
[13]. In multivariate analysis, after adjusting for type of
vascular access, serum albumin, hemoglobin, time since
dialysis initiation, and presence of short stature, there was
no statistically different rate of hospitalization in patients
with spKt/V greater than or less than 1.2 [adjusted rate
ratio (aRR) 1.59; 95% CI 0.98, 2.56] [13]. However,
if the patients were stratified by spKt/V into five subgroups
(< 1.2, 1.2 to < 1.4, 1.4 to < 1.6, 1.6–1.8, > 1.8), after
adjusting for all the factors listed above, patients with a
spKt/V < 1.2 had a significantly higher risk of hospitaliza-
tion than those with an spKt/Vof between 1.2 and 1.4 (aRR
2.46, 95% CI 1.23, 4.94) [13]. These data are shown
graphically in the Fig. 3 [13]. Interestingly, increasing spKt/
V > 1.4 was not associated with a decreased risk for
hospitalization, and in fact, patients with a spKt/V between
1.4 and 1.6 had an increased risk for hospitalization (aRR
Table 4 Adjusted odds ratios of final logistic multivariate model predicting short stature in pediatric hemodialysis patients 15 to < 18 years old
Predictor (222) Odds Ratio (95% Confidence Interval) P value
Male (vs female) 2.6 (1.3–5.2) < 0.01
Congenital/urologic cause of ESRD (vs acquired/other) 2.8 (1.5–5.4) < 0.01
Years on dialysis (per 1 year) 1.2 (1.1–1.4) < 0.001
Increase in spKt/V (0.1 increase) 1.2 (1.1–1.4) < 0.001
Decrease in mean hemoglobin (1 g/dl) 1.3 (1.04–1.6) < 0.05
Candidate factors considered for final model and excluded for nonsignificance: race, ethnicity, albumin < 3.5/3.2 (BCG/BCP), and nPCR
BCG bromcresol green method, BCP bromcresol purple method, ESRD end-stage renal disease, nPCR normalized protein catabolic rate, spKt/V
single-pooled Kt/V
Reprinted from [10], with permission
Table 3 Adjusted odds ratios of final logistic multivariate model predicting short stature in pediatric hemodialysis patients 10 to < 15 years old
Predictor (123) Odds Ratio (95% Confidence Interval) P value
Female (vs male) 2.9 (1.1–7.1) < 0.05
Black (vs white) 3.2 (1.2–9.1) < 0.05
Hispanic (vs non-Hispanic) 4.5 (1.3–15.3) < 0.05
Congenital/urologic cause of ESRD (vs acquired/other) 5.4 (2.1–13.8) < 0.001
Years on dialysis (per 1 year) 1.2 (1.1–1.4) < 0.01
Increase in nPCR (0.1 g/kg/day) 1.3 (1.1–1.5) < 0.01
Candidate factors considered for final model and excluded for nonsignificance: spKt/V, albumin < 3.5/3.2 (BCG/BCP), and hemoglobin
BCG bromcresol green method, BCP bromcresol purple method, ESRD end-stage renal disease, nPCR normalized protein catabolic rate, spKt/V
single-pooled Kt/V
Reprinted from [10], with permission
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spKt/V between 1.2 and 1.4 [13].
A study by Amaral and colleagues linked data from the
ESRD CPM Project to hospitalization and mortality data
from the USRDS to evaluate the relationship between risk
for hospitalization and death and the achievement of the
adult ESRD CPM minimum target hemoglobin ≥ 11 g/dl
[14]. A secondary aim of the study was to assess
differential risk for mortality and hospitalization among
hemoglobin subcategories: < 10, 10 to < 11, 11 to 12, and >
12 g/dl [14]. This study used data from the 2000 and 2001
ESRD CPM study years and linked these data with
hospitalization data from the USRDS through December
2002 and mortality data from the USRDS through
November 2003 [14]. The study included data on 677
patients who had data in either the 2000 or 2001 study year
and who had hospitalization data submitted to the USRDS.
This included 424 patients from the 2000 CPM study year
and 430 patients in the 2001 study year [14]. One hundred
seventy-seven patients had data submitted to both study
years and therefore had repeated measures included in the
analysis [14]. Mean follow-up time for hospitalization
analysis was 1.7±0.9 years; mean follow-up time for
mortality analysis was 2.1±1.3 years [14]. During the
follow-up period, 238 (35%) of the 677 patients were
hospitalized, and there were 54 deaths [14]. Patients with a
hemoglobin < 11 g/dl had a rate of death of 5/100 patient
years versus a rate of 1.9/100 patient years in the group
with a hemoglobin ≥ 11 g/dl (p=0.009) [14]. In multivariate
analysis, hemoglobin ≥ 11 g/dl was associated with a
decreased risk for death [hazard ratio (HR) 0.38, 95% CI
0.20, 0.72]. When hemoglobin was evaluated by the
subcategories listed above, a significant difference in
survival between hemoglobin < 10 g/dl and the other
hemoglobin subcategories was demonstrated, and is shown
in Fig. 4 (p=0.0007; log rank) [14]. There was a trend
toward decreased mortality as hemoglobin increased;
hemoglobin 11–12 g/dl was associated with a 69%
decreased risk for mortality compared with hemoglobin
< 10 g/dl (HR 0.31; 95% CI 0.14, 0.65), and hemoglobin
> 12 g/dl was associated with a 72% decreased risk for
death compared with hemoglobin < 10 g/dl (HR 0.28, 95%
CI 0.13, 0.61) [14].
Unadjusted analysis suggested that a hemoglobin ≥ 11 g/
dl was associated with a decreased risk for hospitalization
(0.31± 0.76 hospitalizations per year at risk vs 0.45±0.87
hospitalizations per year at risk for patients with hemoglo-
bin < 11 g/dl; p=0.0128). However, in multivariate
analysis, this was no longer statistically significant (inci-
dence-rate ratio 0.87; 95% CI 0.66, 1.15) [14]. Evaluation
of risk for hospitalization by hemoglobin subcategories also
did not reveal significant differences [14].
Although these studies demonstrate a strong association
between spKt/V and risk for hospitalization and hemoglo-
bin and risk for mortality, respectively, again, these studies
determine only associations and not cause and effect.
Because the ESRD CPM data were collected after pub-
lished KDOQI recommendations, it is assumed that values
for spKt/V and hemoglobin below the recommended levels
were unintentional [13]. Recall, also, that the study of spKt/
V evaluated delivered, and not prescribed, dose of dialysis
[13]. It is possible that factors that led to reduced delivered
dialysis dose, such as shortened runs secondary to
noncompliance or medical instability, may have also led
to an increased risk for hospitalization [13]. As for the
increased risk for hospitalization seen with spKt/V between
1.4 and 1.6, it is also possible that factors that led to the
higher spKt/V, either prescribed because of some clinical
abnormality such as hyperkalemia or the result of patient
factors such as lower volume of distribution of urea (due to
lower body weight), also contributed to a higher risk for
hospitalization [13]. Similarly, factors that contribute to
Fig. 4 Cumulative survival by hemoglobin categories among adoles-
cent (age 12 to < 18 years) hemodialysis patients. Hemoglobin
categories:
_______ Hgb < 10 g/dl, — Hgb ≥ 10% < 11 g/dl, -
.-
.-
.-
.Hgb
11-12 g/dl,
_____Hgb > 12 g/dl (P=0.007, log rank). Reprinted from
[14], with permission
Fig. 3 Adjusted relative rate of admission in adolescent (age 12 to <
18 years) hemodialysis patients stratified into five groups by single-
pool Kt/V: < 1.2, 1.2–1.4, 1.4–1.6, 1.6–1.8, ≥ 1.8. The group
containing values between 1.2 and 1.4 was used as the referent.
Factors included in the multivariate analysis: serum albumin,
hemoglobin, height standard deviation score, vascular access type,
and time since dialysis initiation. Point estimates and 95% confidence
interval are shown. Reprinted from [13], with permission
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nutrition, and blood loss might also contribute to the higher
mortality rates seen in these patients [14].
Conclusion
Although mortality and hospitalization rates remain unac-
ceptably high in pediatric HD patients compared with the
general pediatric population, death and hospitalization are
infrequent events in pediatric HD patients compared with
the experience in adult HD patients [4, 25]. With fewer than
800 prevalent United States pediatric HD patients, it is
unlikely that meaningful prospective randomized studies
evaluating the impact of intermediate outcomes, such as
dialysis dose and hemoglobin, on the firmer outcomes of
linear growth, hospitalization, and death will ever be
conducted in pediatric patients. Therefore, observational
studies such as the ESRD CPM Project are important to try
to define risk factors for poor outcomes. These studies
suggest that the majority of prevalent pediatric HD patients
in the United States achieve the threshold values estab-
lished by the adult ESRD CPMs. However, data from the
ESRD CPM Project repeatedly demonstrate that despite
controlling for multiple confounders, black race is a
significant risk factor for failing to meet the threshold
spKt/Vof 1.2, a finding that has also been demonstrated in
a cohort of pediatric HD patients enrolled in the North
American Pediatric Renal Trials and Collaborative Studies
[26]. Further study is needed to identify factors responsible
for this phenomenon. Patients who fail to meet the
threshold value for mean albumin are at risk for failing to
reach the threshold value for mean hemoglobin and visa
versa, suggesting that these thresholds can be used as
markers for patients who are doing poorly. This is
emphasized by studies demonstrating that failure to achieve
an spKt/V of 1.2 is associated with an increased risk for
hospitalization and that failure to achieve a hemoglobin of
11 g/dl is associated with an increased risk of death [13,
14]. Taken together, these data suggest that failure to reach
the adult ESRD CPM targets may be a marker of poor
outcomes and alert the physician to investigate causes for
the failure to achieve them.
Multiple-Choice Questions
(Answers appear following the reference list)
1.) The number of PREVALENT pediatric HD patients in
the United States in 2005 was approximately:
A.) 800
B.) 5,000
C.) 1,400
D.) 12,000
2.) Which statement regarding pediatric patients who have
had end-stage kidney disease for more than 24 months
is correct?
A.) The majority of patients are treated with HD
B.) The majority of patients are treated with PD
C.) The majority of patients have received a kidney
transplant
D.) Roughly equal numbers of patients are treated
with dialysis and have received a kidney
transplant
3.) In pediatric HD patients, which factor has been
repeatedly shown to be associated with failing to
achieve a single-pool Kt/V of greater than 1.2?
A.) Male gender
B.) Focal and segmental glomerulosclerosis as cause
of ESRD
C.) Large body mass index
D.) Black race
E.) Hispanic ethnicity
4.) Which of the following statements regarding data from
CMS’ ESRD CPM Project is true:
A.) Data are obtained only on patients for whom
Medicare is primary payor
B.) Data are obtained from administrative reports
C.) Data are obtained from a random sampling of
pediatric dialysis patients
D.) Longitudinal data, or repeated measures, are
obtained on pediatric patients who remain on
dialysis for two or more consecutive study
years
5.) Multivariate analyses in pediatric HD patients using
data from CMS’ ESRD CPM Project and USRDS
have demonstrated which of the following:
A.) Hemoglobin > 11 g/dl is associated with lower
risk for mortality
B.) Single-pool Kt/V greater than 1.4 is associated
with a higher risk for mortality
C.) Single-pool Kt/V lower than 1.2 is associated with
a higher risk of mortality
D.) Hemoglobin < 11 g/dl is associated with a higher
rate of hospitalization
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1.) A
2.) C
3.) D
4.) D
5.) A
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